736 related articles for article (PubMed ID: 24383718)
1. Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement.
Altenhöfer S; Radermacher KA; Kleikers PW; Wingler K; Schmidt HH
Antioxid Redox Signal; 2015 Aug; 23(5):406-27. PubMed ID: 24383718
[TBL] [Abstract][Full Text] [Related]
2. NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS.
Cifuentes-Pagano E; Csanyi G; Pagano PJ
Cell Mol Life Sci; 2012 Jul; 69(14):2315-25. PubMed ID: 22585059
[TBL] [Abstract][Full Text] [Related]
3. Isoform-selective NADPH oxidase inhibitor panel for pharmacological target validation.
Dao VT; Elbatreek MH; Altenhöfer S; Casas AI; Pachado MP; Neullens CT; Knaus UG; Schmidt HHHW
Free Radic Biol Med; 2020 Feb; 148():60-69. PubMed ID: 31883469
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting the Activity of NADPH Oxidase in Cancer.
Konaté MM; Antony S; Doroshow JH
Antioxid Redox Signal; 2020 Aug; 33(6):435-454. PubMed ID: 32008376
[No Abstract] [Full Text] [Related]
5. The NOX toolbox: validating the role of NADPH oxidases in physiology and disease.
Altenhöfer S; Kleikers PW; Radermacher KA; Scheurer P; Rob Hermans JJ; Schiffers P; Ho H; Wingler K; Schmidt HH
Cell Mol Life Sci; 2012 Jul; 69(14):2327-43. PubMed ID: 22648375
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of the seven human NOX isoforms and their inhibitors.
Augsburger F; Filippova A; Rasti D; Seredenina T; Lam M; Maghzal G; Mahiout Z; Jansen-Dürr P; Knaus UG; Doroshow J; Stocker R; Krause KH; Jaquet V
Redox Biol; 2019 Sep; 26():101272. PubMed ID: 31330481
[TBL] [Abstract][Full Text] [Related]
7. New insights on NOX enzymes in the central nervous system.
Nayernia Z; Jaquet V; Krause KH
Antioxid Redox Signal; 2014 Jun; 20(17):2815-37. PubMed ID: 24206089
[TBL] [Abstract][Full Text] [Related]
8. The NADPH Oxidase Family and Its Inhibitors.
Chocry M; Leloup L
Antioxid Redox Signal; 2020 Aug; 33(5):332-353. PubMed ID: 31826639
[No Abstract] [Full Text] [Related]
9. Current status of NADPH oxidase research in cardiovascular pharmacology.
Rodiño-Janeiro BK; Paradela-Dobarro B; Castiñeiras-Landeira MI; Raposeiras-Roubín S; González-Juanatey JR; Alvarez E
Vasc Health Risk Manag; 2013; 9():401-28. PubMed ID: 23983473
[TBL] [Abstract][Full Text] [Related]
10. Selective inactivation of NADPH oxidase 2 causes regression of vascularization and the size and stability of atherosclerotic plaques.
Quesada IM; Lucero A; Amaya C; Meijles DN; Cifuentes ME; Pagano PJ; Castro C
Atherosclerosis; 2015 Oct; 242(2):469-75. PubMed ID: 26298737
[TBL] [Abstract][Full Text] [Related]
11. Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases.
Lu J; Risbood P; Kane CT; Hossain MT; Anderson L; Hill K; Monks A; Wu Y; Antony S; Juhasz A; Liu H; Jiang G; Harris E; Roy K; Meitzler JL; Konaté M; Doroshow JH
Biochem Pharmacol; 2017 Nov; 143():25-38. PubMed ID: 28709950
[TBL] [Abstract][Full Text] [Related]
12. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent.
Aoyama T; Paik YH; Watanabe S; Laleu B; Gaggini F; Fioraso-Cartier L; Molango S; Heitz F; Merlot C; Szyndralewiez C; Page P; Brenner DA
Hepatology; 2012 Dec; 56(6):2316-27. PubMed ID: 22806357
[TBL] [Abstract][Full Text] [Related]
13. NADPH Oxidase Inhibition: Preclinical and Clinical Studies in Diabetic Complications.
Urner S; Ho F; Jha JC; Ziegler D; Jandeleit-Dahm K
Antioxid Redox Signal; 2020 Aug; 33(6):415-434. PubMed ID: 32008354
[No Abstract] [Full Text] [Related]
14. NADPH oxidases in heart failure: poachers or gamekeepers?
Zhang M; Perino A; Ghigo A; Hirsch E; Shah AM
Antioxid Redox Signal; 2013 Mar; 18(9):1024-41. PubMed ID: 22747566
[TBL] [Abstract][Full Text] [Related]
15. The quest for selective nox inhibitors and therapeutics: challenges, triumphs and pitfalls.
Cifuentes-Pagano E; Meijles DN; Pagano PJ
Antioxid Redox Signal; 2014 Jun; 20(17):2741-54. PubMed ID: 24070014
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA Targeting Nicotinamide Adenine Dinucleotide Phosphate Oxidases in Cancer.
Kushwaha PP; Gupta S; Singh AK; Prajapati KS; Shuaib M; Kumar S
Antioxid Redox Signal; 2020 Feb; 32(5):267-284. PubMed ID: 31656079
[No Abstract] [Full Text] [Related]
17. Opportunity nox: the future of NADPH oxidases as therapeutic targets in cardiovascular disease.
Streeter J; Thiel W; Brieger K; Miller FJ
Cardiovasc Ther; 2013 Jun; 31(3):125-37. PubMed ID: 22280098
[TBL] [Abstract][Full Text] [Related]
18. Nicotinamide Adenosine Dinucleotide Phosphate Oxidase-Mediated Signaling in Cardiac Remodeling.
Visnagri A; Oexner RR; Kmiotek-Wasylewska K; Zhang M; Zoccarato A; Shah AM
Antioxid Redox Signal; 2023 Feb; 38(4-6):371-387. PubMed ID: 36656669
[No Abstract] [Full Text] [Related]
19. Nox NADPH oxidases and the endoplasmic reticulum.
Laurindo FR; Araujo TL; Abrahão TB
Antioxid Redox Signal; 2014 Jun; 20(17):2755-75. PubMed ID: 24386930
[TBL] [Abstract][Full Text] [Related]
20. NOX Inhibitors: From Bench to Naxibs to Bedside.
Elbatreek MH; Mucke H; Schmidt HHHW
Handb Exp Pharmacol; 2021; 264():145-168. PubMed ID: 32780287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
